← Back to Search

Contingency Management for Psychosis

N/A
Recruiting
Led By Rachel Rabin, Ph. D.
Research Sponsored by Douglas Mental Health University Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Must not have
Taking psychotropic medication
Head injury requiring hospitalization or loss of consciousness > 5 minutes
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, day 28
Awards & highlights
No Placebo-Only Group

Summary

This trial will study the brain changes of people with psychosis who stop using cannabis for 28 days, compared to a control group who continue using.

Who is the study for?
This trial is for adults who use cannabis heavily and either have psychosis or no psychiatric conditions. Participants must speak English or French, have an IQ over 75, and be stable on medications if they have psychosis. They can't join if they use other psychoactive substances, are suicidal, pregnant, need hospitalization for medical issues, take psychotropic meds (except those with psychosis), or have MRI contraindications.
What is being tested?
The study examines how stopping cannabis affects brain function in people with and without psychosis over 28 days. It involves random assignment to a group that quits using cannabis or a control group that continues as usual. Brain changes will be monitored using MRI scans before and after the abstinence period.
What are the potential side effects?
There may not be direct side effects from the interventions since this trial focuses on observing changes during cannabis abstinence rather than testing a drug; however, participants might experience withdrawal symptoms like irritability, sleep problems, cravings for cannabis or mood swings.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently taking medication for my mental health.
Select...
I have been hospitalized for a head injury or was unconscious for more than 5 minutes.
Select...
I have a medical condition that needs regular hospital visits.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, day 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, day 28 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in behavior during fMRI task
Change in fMRI brain activity pattern
Secondary study objectives
Change in brain morphology: cortical thickness
Change in brain morphology: diffusion
Change in brain morphology: gray matter volume

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

5Treatment groups
Experimental Treatment
Active Control
Group I: Psychosis patients with cannabis use (Abstinent)Experimental Treatment1 Intervention
Psychosis patients with cannabis use will receive contingency management to encourage cannabis abstinence for 28 days
Group II: Non-Psychiatric controls with cannabis use (Abstinent)Experimental Treatment1 Intervention
Non-Psychiatric controls with cannabis use will receive contingency management to encourage cannabis abstinence for 28 days
Group III: Psychosis patients with cannabis use (Non-abstinent)Active Control1 Intervention
Psychosis Patients with cannabis use who will continue to use cannabis as usual
Group IV: Non-Psychiatric controls with cannabis use (Non-abstinent)Active Control1 Intervention
Non-Psychiatric Controls with cannabis use will continue to use cannabis as usual
Group V: Non-Psychiatric Controls without cannabis useActive Control1 Intervention
Non-Psychiatric controls without cannabis use
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Contingency management
2006
Completed Phase 4
~1020

Find a Location

Who is running the clinical trial?

Douglas Mental Health University InstituteLead Sponsor
29 Previous Clinical Trials
2,614 Total Patients Enrolled
Rachel Rabin, Ph. D.Principal InvestigatorDouglas Mental Health University Institute

Media Library

Contingency management Clinical Trial Eligibility Overview. Trial Name: NCT05445180 — N/A
Cannabis Use Disorder Research Study Groups: Psychosis patients with cannabis use (Non-abstinent), Non-Psychiatric controls with cannabis use (Abstinent), Non-Psychiatric controls with cannabis use (Non-abstinent), Non-Psychiatric Controls without cannabis use, Psychosis patients with cannabis use (Abstinent)
Cannabis Use Disorder Clinical Trial 2023: Contingency management Highlights & Side Effects. Trial Name: NCT05445180 — N/A
Contingency management 2023 Treatment Timeline for Medical Study. Trial Name: NCT05445180 — N/A
~65 spots leftby May 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top